血管造影动力(ANGO)
icon
搜索文档
AngioDynamics(ANGO) - 2021 Q1 - Quarterly Report
2020-10-08 04:18
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3146460 (State or other juris ...
AngioDynamics(ANGO) - 2021 Q1 - Earnings Call Transcript
2020-09-30 00:32
AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2021 Results Conference Call September 29, 2020 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - EVP and CFO Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Jayson Bedford - Raymond James Cecilia Furlong - Canaccord Genuity Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2021 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...
AngioDynamics(ANGO) - 2020 Q4 - Annual Report
2020-08-10 19:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |------------------------------------------|---------------------------------|-----------------------------------------------------------|---------------------------------------- ...
AngioDynamics(ANGO) - 2020 Q3 - Quarterly Report
2020-04-09 03:56
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-50761 AngioDynamics, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3146460 (State or other jur ...
AngioDynamics(ANGO) - 2020 Q2 - Quarterly Report
2020-01-09 03:39
Table of Contents Title of each class Trading symbol Name of each exchange on which registered Common stock, par value $.01 ANGO NASDAQ Global Select Market Preferred Stock Purchase Rights NASDAQ Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...
AngioDynamics(ANGO) - 2020 Q1 - Quarterly Report
2019-10-05 03:37
Table of Contents Title of each class Trading symbol Name of each exchange on which registered Common stock, par value $.01 ANGO NASDAQ Global Select Market Preferred Stock Purchase Rights NASDAQ Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...